Immunome/$IMNM
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Immunome
Immunome Inc is a biotechnology company focused on developing first-in-class targeted oncology therapies. The company specializes in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics. Its pipeline includes varegacestat, an investigational oral gamma secretase inhibitor that reported positive topline results in the Phase 3 RINGSIDE trial for progressing desmoid tumors; IM-1021, a ROR1 antibody-drug conjugate under evaluation in a Phase 1 trial; and IM-3050, a FAP-targeted radioligand therapy with IND clearance and a planned Phase 1 trial. The company is also advancing preclinical solid tumor ADCs, including IM-1617, IM-1340, and IM-1335.
- Ticker
- $IMNM
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 247
- Headquarters
- Bothell, United States
- Website
- immunome.com
Immunome Metrics
BasicAdvanced
$2.1B
-
-$2.49
2.12
-
Price and volume
Market cap
$2.1B
Beta
2.12
52-week high
$30.06
52-week low
$14.64
Average daily volume
1.4M
Financial strength
Current ratio
15.077
Quick ratio
14.636
Long term debt to equity
0.009
Total debt to equity
0.009
Profitability
EBITDA (TTM)
-257.687
Management effectiveness
Return on assets (TTM)
-37.78%
Return on equity (TTM)
-64.03%
Valuation
Price to book
3.93
Price to tangible book (TTM)
3.93
Price to free cash flow (TTM)
-8.17
Free cash flow yield (TTM)
-12.24%
Free cash flow per share (TTM)
-2.229
Growth
Revenue change (TTM)
-100.00%
Earnings per share change (TTM)
-15.40%
3-year earnings per share growth (CAGR)
4.12%
What the Analysts think about Immunome
Analyst ratings (Buy, Hold, Sell) for Immunome stock.
Analyst projections of the future price of Immunome stock.
Bulls say / Bears say
Varegacestat produced strong Phase 3 results: it cut the risk of progression or death by 84%, and the confirmed response rate was 56% versus 9% on placebo. This gives Immunome a compelling lead asset in a rare tumour type. (Immunome)
The FDA accepted varegacestat’s application and set an action date of 28 April 2027. That is a meaningful regulatory step, though approval is not yet assured. (Immunome)
Immunome has other clinical programmes beyond its lead drug: its Phase 1 IM-1021 trial has recorded objective responses in B-cell lymphoma, and the first patient has been dosed in the IM-3050 trial. This gives investors additional, early-stage opportunities if varegacestat is approved. (Immunome)
Varegacestat would enter a market where Ogsiveo is already an approved treatment and has an established foothold. The two drugs are in the same class, and there is no head-to-head trial showing varegacestat is better. (OncoDaily)
The Phase 3 trial reported diarrhoea in 82% of patients, fatigue in 44% and rash in 43%. Even if most events were low grade, these side effects could matter for patients taking treatment over a long period. (OncoDaily)
Immunome paid $20 million and issued about 4.43 million shares to secure full patent rights to varegacestat, diluting existing holders before the company has product revenue. The deal removes future royalty and milestone payments, but the upfront cost is substantial. (StockTitan, StockTitan)
Data summarised monthly by Lightyear AI. Last updated on 6 Oct 2026.
Immunome Financial Performance
Revenues and expenses
Immunome Earnings Performance
Company profitability
Upcoming events
No upcoming events
Immunome News
AllArticlesVideos
Immunome Announces EMA Validation of Marketing Authorization Application for Varegacestat for the Treatment of Adults with Desmoid Tumors
Business Wire2 days ago
Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Business Wire4 weeks ago
Immunome Announces IND Clearance for IM-1340, a Potential First-in-Class Antibody-Drug Conjugate for the Treatment of Solid Tumors
Business Wire1 month ago
Funds containing Immunome
Fund name | Fund size | $IMNM weighting |
|---|---|---|
iShares Healthcare Innovation£DRDR | $1.3B | 0.20% |
iShares Healthcare Innovation€2B78 | $1.2B | 0.20% |
iShares Healthcare Innovation$HEAL | $1.3B | 0.20% |
iShares Ageing Population$AGED | $953M | 0.18% |
iShares Ageing Population£AGES | $953M | 0.18% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.